May #59 : Welcome To Conservatism - by Lark Lands

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

Fitness 2000

Big Trouble

Size Matters

This Little Drug Went To Market

The New Opiate for the Masses

The Attack of the Killer Causes

Editor's Letter

Mailbox

Merging Medicine Chests

Kaiser Rolled

Catching Up With…

Action Jackson

A Great Hydeia

NEG/POS

Deaf Jam

A Signal Man

A Queen Who Cares

Lensing Up

Festival Fare

Mastur Class

Covered Reflections

Paradise Paradigms

Milestones

President Nader

War Paint

Welcome To Conservatism

Put Up Your Nukes

Shelf Life

Time For An E-Full

Work In Progress

Work In Progress

Comfort Zone

Get High on Glutathione

Herb Of The Month

5.2.89: Take Two



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

May 2000

Welcome To Conservatism

by Lark Lands

What do you call it when the year’s big news in treatment is postponing or stopping it? Lark Lands says it’s progress.

You could have heard a pin drop!” Well, in a hall seating hundreds of AIDS researchers and activists at San Francisco’s Seventh Conference on Retroviruses and Opportunistic Infections, this certainly wasn’t the case. But what is true is that that hard-to-please crowd erupted into applause  when—after years of big talk about hitting the virus with drugs and little attention to the side effects—William Powderly, MD, a leading AIDS researcher at Washington University, gazed out at his audience and said, “The goal of antiretroviral therapy that we’ve all agreed upon is that we should maximally suppress, with the best tolerated regimen, viral replication....That has become the mantra.... But that is not the goal of treatment. The goal of treatment is that we prolong meaningful survival for our patients.” Behind Powderly was a giant projection of a Star Trek–like spaceship and Mr. Spock’s famous motto, adapted: “(Let your patient) live long and prosper.”

And therein lie the rubs. At the symposium on HAART side effects at which Powderly was speaking, and in hundreds of scientific posters, there was an overwhelming barrage of information on drug toxicities—neuropathy, muscle inflammation, pancreatitis, liver problems, lactic acidosis, fat redistribution, insulin resistance, elevated blood fats, osteoporosis and more. Along with that list came the admission that there’s an immense amount we don’t yet understand about these side effects. We don’t know how many HIVers have them, or what causes them, or how they work, or, perhaps most pressing, what the long-term consequences are. In other words, no one can tell you what your risk is of getting sick or even dying from HAART-induced heart disease, diabetic complications or bone fractures from osteoporosis. All we know is that you have some risk.

That’s one rub. The other is, at what point are HAART-takers who have such problems no longer experiencing meaningful survival? And while that call is up to each HIVer alone, aren’t these consequences serious enough to make us take another look at the current guidelines trumpeting early intervention with these potent but toxic drugs? (See “Put Up Your Nukes,”.) Powderly’s conclusion, reflecting a sea change in medical opinion, was a much-appreciated yes.

Call it the new treatment conservatism. Since the two great hypotheses on which the hit-early-and-hard strategy was based have proved false—combo therapy doesn’t totally stop the virus in a manner that affords a cure, and damage to the immune system isn’t irreversible—we must consider with great care the consequences of treating people for a very long time with drugs that have so much potential for harm.

“And therefore,” Powderly said, “we should be asking whether somebody who has no symptoms and no immediate risk of clinical progression should be exposed to these drugs at all, or at least not until they need them.” Based on chatting in the hallways and schmoozing at the hotels, it would seem that many researchers agree with Powderly, and that many clinicians have already adopted more conservative strategies when it comes to initiating treatment.

Powderly offered up another once-heretical notion—that structured treatment interruptions (see “Happy Holidays?” in POZ, December 1999 for more about these planned drug holidays) might provide not only improved immune responses to HIV, but also maintain the CD4 count at a safe level while minimizing exposure to toxic drugs. He cautioned, however, that STIs are potentially risky and require much additional study.

Then, voicing what was the unspoken theme on many minds, Powderly called for the design of new studies “that address the issues of using drugs for life or, if not for life, at least for a very long time.” And he closed with what could serve as the new message for the new age: “We need to figure out what is the right way to treat patients with antiretroviral therapy. Not for the short term but rather for the long—and hopefully successful—haul.” Amen, brother.




[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Should the U.S. gay blood ban end?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.